Studies have shown that the inhibition of ERK1/2 activity leads to the phosphorylation and activation of the ERK5 pathway in various cancers, promoting the malignant proliferation of cancer cells, which may be a potential key reason why existing ERK1/2-targeted inhibitors have not achieved the expected effects. The gene discussed is MAPK3; the disease is cancer.